HETEROARYL DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt th...

Full description

Saved in:
Bibliographic Details
Main Authors TILEKAR, Ajay, Ramchandra, GUPTA, Nishant, Ramniwasji, KARCHE, Navnath, Popat, KAMBOJ, Rajender, Kumar, JADHAV, Ganesh, Rajaram, KURHADE, Sanjay, Pralhad, SINHA, Neelima, PALLE, Venkata, P
Format Patent
LanguageEnglish
French
Published 23.02.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject. L'invention concerne des composés de formule (I), leurs formes tautomères, stéréoisomères, et des sels pharmaceutiquement acceptables de ceux-ci. Dans ladite formule, le cycle Ar, le cycle B, R1 à R5, X, Y, p, q, r, et s ont la signification indiquée dans la description. L'invention concerne également des compositions pharmaceutiques comprenant un composé, un tautomère, un stéréoisomère, ou un sel de celui-ci, et des méthodes de traitement ou de prévention de maladies ou de troubles, par exemple, le cancer, dont le traitement ou la prévention peut s'effectuer par inhibition de l'enzyme PARP d'un patient.
Bibliography:Application Number: WO2016IB54886